医学
随机对照试验
清晰
临床试验
事件(粒子物理)
物理疗法
重症监护医学
外科
内科学
生物化学
化学
物理
量子力学
作者
John Gregson,D. R. Fraser Taylor,Ruth Owen,Timothy Collier,David J. Cohen,Stuart Pocock
出处
期刊:Circulation
[Lippincott Williams & Wilkins]
日期:2025-06-02
卷期号:151 (22): 1606-1619
被引量:14
标识
DOI:10.1161/circulationaha.124.070251
摘要
The win ratio is a method for analyzing a hierarchical composite outcome. It has been most widely used in randomized clinical trials (RCTs) in cardiovascular disease. We performed a review of cardiovascular RCTs using the win ratio published between January 2022 and July 2024. The aims were to summarize current use and to provide examples to illustrate effective use and communication. We identified 36 eligible RCTs, mainly in heart failure and ischemic heart disease. Intervention was pharmaceutical in 26, a procedure in 7, and treatment strategy in 3 trials. When outcomes were analyzed with both conventional composite end points or hierarchical analysis, the conclusions tended to be similar. The win ratio was often used to combine evidence from event outcomes and quantitative measures together in a hierarchical composite, as was done in 23 RCTs. It was also used to create a clinically more relevant measure in RCTs by recognizing the clinical priorities among event outcomes. Selected example RCTs illustrate how the clarity of win ratio findings can be improved by (1) complementing the win ratio (a relative measure) with the win difference, (2) identifying which components of a hierarchical composite drive the overall results, and (3) clearly prespecifying the outcomes and win ratio analysis to be used. We conclude with a set of recommendations for future use of hierarchical composite outcomes and the win ratio. When used wisely, the win ratio is a valuable tool in the analysis of RCTs.
科研通智能强力驱动
Strongly Powered by AbleSci AI